【摘 要】
：
An increasing body of evidence has shown that the amino acid changes at position 1298 might eliminate methylenetetrahydrofolate reductase (MTHFR) enzyme act
论文部分内容阅读
An increasing body of evidence has shown that the amino acid changes at position 1298 might eliminate methylenetetrahydrofolate reductase (MTHFR) enzyme activity, leading to insufficient folic acid and subsequent human chromosome breakage.Epidemiological studies have linked MTHFR single-nucleotide polymorphism (SNP) rs1801131 to myeloid leukemia risk, with considerable discrepancy in their results.We therefore were prompted to clarify this issue by use of ameta-analysis.The search terms were used to cover the possible reports in the MEDLINE, Web of Knowledge, and China National Knowledge Infrastructure (CNKI)databases.Odds ratios were estimated to assess the association of SNP rs1801131 with myeloid leukemia risk.
其他文献
目的 通过体外实验研究利巴韦林对白血病细胞株K562和U937增殖、凋亡以及eIF4E、cyclinD1(CCND1)、c-myc等基因表达水平的影响，探讨利巴韦林抗白血病作用的相关机制。方法
Background Multiple myeloma (MM) is a malignant proliferative disease which is characterized by excessive proliferation of abnormal plasma cell originated f
目的 研讨降钙素原(procalcitonin,PCT)联合C-反应蛋白(C-reactive protein,CRP)检测在白血病化疗后粒缺伴发热患者对感染诊断的临床意义.方法 回顾性分析中国医科大学附
Background and Objective Cyclosporine A (CsA) has been used as immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for
目的 检测急性髓系白血病(acute myeloid leukemia,AML)患者骨髓单个核细胞中GPX3(glutathione peroxidase 3)基因启动子甲基化的状态并探讨其临床意义以及对GPX3表达的
Background New evidence has questioned the role of high-dose cytarabine (HDAC) in consolidation therapy of acute myeloid leukemia (AML) in first complete re
目的 检测急性髓系白血病(acute myeloid leukemia,AML)患者骨髓中DLX4 (distal-less homeobox 4)基因2个异构体的表达态势并探讨其临床意义。方法 收集102例初诊AML患者
目的 检测急性髓系白血病(acute myeloid leukemia,AML)患者骨髓单个核细胞中BAALC (brain and acute leukemia,cytoplasmic)基因的表达并探讨其临床意义。方法 收集121
目的 检测急性髓系白血病(acute myeloid leukemia,AML)患者骨髓单个核细胞中GPX3(glutathione peroxidase 3)基因启动子甲基化的状态并探讨其临床意义以及对GPX3表达的
The right dose of daunorubicin (DNR) for the treatment of newly diagnosed acute myeloid leukemia (AML)is uncertain.Previous trials have shown conflicting re